Gongwin Biopharm Holdings
6617.TWO
3.50 USD
0.03
+0.86%
g
Overview
Last close
3.50 usd
Market cap
396.56M usd
52 week high
6.84 usd
52 week low
2.99 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
455.8947
Price/Book Value
4.4912
Enterprise Value
366.34M usd
EV/Revenue
378.174
EV/EBITDA
-167.232
Key financials
Revenue TTM
967002.13 usd
Gross Profit TTM
701555.35 usd
EBITDA TTM
-3.97M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd
About
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
- Symbol6617.TWO
- ExchangeTWO
- IsinN/A
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEO
- HeadquarterTaipei
- Web sitehttps://www.gongwinbiopharm.com
